An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
Public ClinicalTrials.gov record NCT03664960. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
Study identification
- NCT ID
- NCT03664960
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Allakos Inc.
- Industry
- Enrollment
- 58 participants
Conditions and interventions
Interventions
- AK002 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 13, 2018
- Primary completion
- Nov 1, 2021
- Completion
- Nov 1, 2021
- Last update posted
- Feb 27, 2024
2018 – 2021
United States locations
- U.S. sites
- 17
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phoenician Centers for Research and Innovation | Phoenix | Arizona | 85021 | — |
| Mayo Clinic Arizona | Scottsdale | Arizona | 85259 | — |
| Ventura Clinical Trials | Ventura | California | 93003 | — |
| Advanced Research Institute | New Port Richey | Florida | 34653 | — |
| Northwestern | Chicago | Illinois | 60611 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| NIH | Bethesda | Maryland | 20892 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Mount Sinai | New York | New York | 10029 | — |
| University of North Carolina - Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Cincinnati Children's Hospital | Cincinnati | Ohio | 45229 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| ClinSearch | Chattanooga | Tennessee | 37421 | — |
| Vanderbilt University | Nashville | Tennessee | 37212 | — |
| Avant Research Associates | Austin | Texas | 78704 | — |
| University of Utah | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03664960, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2024 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03664960 live on ClinicalTrials.gov.